LAG3 and metastatic melanoma: In the blood of patients with metastatic melanoma treated with relatlimab (anti-LAG-3) and nivolumab (anti-PD-1) the “adaptive” NK cell subset exhibited the highest LAG-3 expression, and responding patient NK cells were activated with treatment (348).